Clinical trial · Observational
A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate
A Multi-Center Observational Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate (BONDORAL)
NCT02528747CI-TRIAL-00018894completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational, multicenter survey is designed to assess the efficacy of oral ibandronate in adults with breast cancer and metastatic bone disease. Data on the use of ibandronate in clinical practice will be collected from Hungarian patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Study population
- description
- Breast cancer patients with metastatic bone disease
Primary outcomes (1)
- measure
- Change in bone pain according to Visual Analog Scale (VAS) score
- timeFrame
- From Baseline to the end of 1 year
Secondary outcomes (2)
- measure
- Compliance with tablet formulation of ibandronate according to Case Report Form (CRF) questionnaire
- timeFrame
- Up to approximately 1 year
- measure
- Incidence of adverse events
- timeFrame
- Up to approximately 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults at least 18 years of age * Histologically confirmed breast cancer with bone metastasis * Receiving or indicated for the tablet formulation of ibandronate according to the summary of product characteristics (SmPC) and local labeling Exclusion Criteria: * Contraindication to ibandronate according to SmPC * Ongoing participation in any trial evaluating the efficacy and/or safety of ibandronate
References
Publications (0)
Data not yet available
No reference posted for this study.